Monitoring of Suspected Adverse Drug Reactions in Oncology Unit ...

International Journal of Research in Pharmaceutical and Biomedical Sciences ISSN: 2229-3701
35. Olsson S. The role of the WHO Programme for International Drug Monitoring in coordinating
worldwide drug safety efforts. Drug Safety 1998; 19(1): 1-10.
36. Pirmohamed M, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of
18820 patients. Br Med J 2004, 329: 15-9.
37. Rieder MJ. Mechanisms of unpredictable adverse drug reactions. Drug Saf 1994; 11: 196-212.
38. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003;
24: 253-62.
39. Skeel TR. Handbook of cancer chemotherapy. 5th ed. Philadelphia: Lippincott Williams & Wilkins;
1999.
40. Somberg JC. Reactions to prescribed drugs kill thousands annually [Editorial]. Am J Ther 1998; 5:
133.
41. The Uppsala Monitoring Centre. The use of the WHO-UMC system for standardized case causality
assessment [Monograph on the internet]. The centre; 2005 [cited 2005 Nov 19]. Available from:
http://www.who-umc.org/pdfs/Causality.pdf.
42. van Grootheest AC, de Jong-van den Berg LT. The role of hospital and community pharmacists in
pharmacovigilance. Res Social Adm Pharm 2005; 1: 126-33.
43. van Grootheest K, de Graaf L, de Jong-van den Berg LT. Consumer adverse drug reaction reporting: a
new step in pharmacovigilance? Drug Saf 2003; 26: 211-7.
44. van Grootheest K, de Jong-van den Berg L. Patients' role in reporting adverse drug reactions. Expert
Opin Drug Saf 2004; 3: 363-8.
45. Vervloet D, Durham S. Adverse reactions to drugs. Br Med J 1998; 316: 1511-4.
46. Wood L, Martinez C. The general practice research database: role in pharmacovigilance. Drug Saf
2004; 27: 871-81.
47. World Health Organization. Improving pharmacovigilance practice beyond spontaneous reporting.
World Health Orgn Drug Info 2004; 18: 203-6.
48. World Health Organization. International drug monitoring: the role of national centres. [Report of a
WHO meeting]. World Health Orgn Tech Rep Ser 1972; 498: 1-25.
49. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal
products. Geneva: World Health Organization & The Uppsala Monitoring Centre, 2002.
50. World Health Organization. The safety of medicines in public health programmes: pharmacovigilance
as an essential tool. Geneva: WHO, 2006.
Vol. 1 (2) Oct – Dec 2010 www.ijrpbsonline.com 32